SCHEMBL1973501

SCHEMBL1973501

O=C(Nc1cccc(Cl)n1)c1ccc2[nH]c(Nc3c(Cl)cccc3Cl)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.52
NPC1 O15118 7/20 0.47
RAB9A P51151 6/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
MCL1 Q07820 1/20 0.44
MAOB P27338 3/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
DGAT1 O75907 1/20 0.42
PKM P14618 1/20 0.42
TP53 P04637 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1974207 0.90 NPC1 (0.54) GRM5NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL1966375 0.88 LCK (0.49) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL1975367 0.87 NPC1 (0.43) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL1975926 0.86 NPC1 (0.47) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL13392916 0.86 SORT1 (0.45) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL1972260 0.85 KMT2A (0.57) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL1974445 0.85 KMT2A (0.50) GRM5NPC1RAB9AKMT2AMEN1
SCHEMBL13393121 0.85 HDAC11 (0.41) GRM5NPC1RAB9AKMT2AMEN1
SCHEMBL16364384 0.85 NPC1 (0.54) NPC1RAB9AKMT2AMEN1SMN1; SMN2
SCHEMBL13393490 0.85 NPC1 (0.51) NPC1RAB9AKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP claimed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
WO-2010034796-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 GRM5 2421/4885NPC1 4650/4885RAB9A 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.